Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BN ImmunoTherapeutics, a subsidiary of Bavarian Nordic, has partnered with National Cancer Institute (NCI) to develop vaccine product candidates for cancer treatment.
Subscribe to our email newsletter
The companies, under the licensing and Cooperative Research and Development Agreements (CRADA) will also develop a technology platform based on NCI’s cancer vaccine technology.
In addition, Bavarian Nordic has obtained certain rights to CVAC-301, an off-the-shelf, cancer immunotherapy product candidate.
The drug is designed using the company’s poxvirus technology platform and is the subject of randomized Phase 2 study of docetaxel alone or in combination with CVAC-301 in metastatic breast cancer. The study is sponsored by NCI.
Under the agreement the company will manufacture additional vaccine constructs for the NCI, which inturn will fund and conduct certain preclinical and clinical studies to evaluate the product.